Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

aristo pharma gmbh - hydrochlorthiazid, losartankalium - filmovertrukne tabletter - 100+25 mg

Den Europæiske Union - dansk - EMA (European Medicines Agency)

teva pharma b.v. - budesonide, formoterol - astma - medicin for obstruktiv sygdomme, - budesonid / formoterol teva pharma b. indikeres kun hos voksne 18 år og ældre. asthmabudesonide/formoterol teva pharma b. is indicated in the regular treatment of asthma, where use of a combination (inhaled corticosteroid and long-acting β2 adrenoceptor agonist) is appropriate: orin patients not adequately controlled with inhaled corticosteroids and “as needed” inhaled short-acting β2 adrenoceptor agonists. in patients already adequately controlled on both inhaled corticosteroids and long-acting β2 adrenoceptor agonists.

Den Europæiske Union - dansk - EMA (European Medicines Agency)

taw pharma (ireland) limited - clopidogrelhydrochlorid - peripheral vascular diseases; stroke; myocardial infarction; acute coronary syndrome - antitrombotiske midler - , , , , secondary prevention of atherothrombotic events, , clopidogrel is indicated in: , - adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease. , - adult patients suffering from acute coronary syndrome:,    - non-st segment elevation acute coronary syndrome (unstable angina or non-q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa). ,     - st segment elevation acute myocardial infarction, in combination with asa in medically treated patients eligible for thrombolytic therapy. , , in patients with moderate to high-risk transient ischaemic attack (tia) or minor ischaemic stroke (is), clopidogrel in combination with asa is indicated in:, - adult patients with moderate to high-risk tia (abcd2  score ≥4) or minor is (nihss  ≤3) within 24 hours of either the tia or is event.  , , prevention of atherothrombotic and thromboembolic events in atrial fibrillation, in adult patients with atrial fibrillation who have at least one risk factor for vascular events, are not suitable for treatment with vitamin k antagonists (vka) and who have a low bleeding risk, clopidogrel is indicated in combination with asa for the prevention of atherothrombotic and thromboembolic events, including stroke. , , for further information please refer to section 5. , , ,.

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

sandoz a/s - vancomycinhydrochlorid - pulver til infusionsvæske, opløsning - 500 mg

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

strides pharma (cyprus) limited - vancomycinhydrochlorid - kapsler, hårde - 125 mg

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

xellia pharmaceuticals aps - vancomycinhydrochlorid - pulver til infusionsvæske, opløsning - 500 mg

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

laboratorio reig jofre s.a. - vancomycin - pulver til koncentrat til infusionsvæske, opløsning - 1000 mg

Den Europæiske Union - dansk - EMA (European Medicines Agency)

pfizer europe ma eeig - dacomitinib monohydrat - carcinom, ikke-småcellet lunge - antineoplastiske midler - vizimpro, som monoterapi, er angivet for den første linje behandling af voksne patienter med lokalt fremskreden eller metastatisk ikke-småcellet lungekræft (nsclc) med epidermal growth factor receptor (egfr) aktiverende mutationer.

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

nordic prime aps - mometasonfuroat - kutanopløsning - 1 mg/ml

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

abbvie a/s - brimonidintartrat, timololmaleat - øjendråber, opløsning - 2+5 mg/ml